Oral thin films are solid unit dosage forms of films designed to be placed on the tongue or any other location in the oral cavity. These films dissolve or disintegrate rapidly in thesaliva, releasing the drug incorporated in the films. These are being increasingly used various drug delivery applications as they provide improved convenience, accessibility, compliance, and bioavailabilitycompared to conventional dosage forms.

The global oral thin films market is estimated to be valued at US$ 3335.68 Mn in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Oral thin films witness high growth owing to increasing patient compliance, as it provides quick and easy oral drug administration without water. It is convenient for patients who are unable to swallow tablets or capsules or have difficulty in swallowing conventional oral medication. Another major driver propelling growth of the oral thin films market is improved bioavailability compared to conventional dosage forms. Oral thin films dissolve in the oral cavity very quickly and deliver the drug directly into the systemic circulation leading to enhanced drug bioavailability. This allows reduction in dosage and frequency of drug administration resulting in better efficacy. All these factors coupled with convenience and affordability offered by oral thin films are expected to contribute significantly to growth of the oral thin films market over the forecast period.

SWOT Analysis

Strength:

Oral thin films offer a non-invasive way for drug delivery compared to tablets or capsules. This makes them a more convenient option for patients who have difficulty swallowing traditional oral formulations.
They are rapidly dissolved in the oral cavity, allowing for faster absorption of the drug into the bloodstream as compared to tablets. This property enables quick onset of action.
The thin film technology allows for inclusion of both hydrophobic and hydrophilic actives into a single dosage form. This opens up new opportunities for development of combination drug therapies.

Weakness:
Achieving an optimal balance between the required drug loading and mechanical integrity of the thin film remains a technological challenge. Excessive drug loading can make the film rigid and difficult to administer.
Factors like temperature and humidity can impact the stability and shelf life of oral thin films. Special packaging is required for protection.

Opportunity:
The elderly population globally is on the rise. Age-related conditions like dysphagia are also increasing. Oral thin films provide an ease of administration benefit particularly suitable for the geriatric demographic.
Novel drug delivery of biologics using oral thin film technology is an emerging area of research. Successful development could help bypass injection-based delivery and improve patient compliance for biologic therapies.

Threats:
The market is highly competitive with presence of both innovator and generic drug manufacturers. New entrants must differentiate their products to gain market share.
Acceptance amongst patients and healthcare professionals relies on demonstration of efficacy and safety advantages over existing oral solid dosage forms.

Key Takeaways

The global Oral Thin Films Market Share  is expected to witness high growth over the forecast period of 2024 to 2031 registering a CAGR of 5.5%. Growth will be driven by rising demand for convenient dosage forms and technological advancements expanding capability of thin film drug delivery.

North America currently dominates the market owing to presence of major pharmaceutical companies and supportive regulatory environment for new drug delivery technologies. Europe follows as the second largest regional market supported by advanced healthcare infrastructure and availability of private and public health insurance coverage in key country markets like Germany and United Kingdom. Asia Pacific is expected to emerge as the fastest growing regional market for oral thin films. This growth can be attributed to rapidly increasing healthcare spending, expanding patient pool affected by chronic conditions, and growing adoption of innovative drug delivery technologies.

Key players operating in the oral thin films market are Purdue Pharmaceuticals L.P., Titan Pharmaceuticals, Inc., Pfizer Inc., Mallinckrodt, Pfizer Inc., Assertio Holdings, Inc., Par Pharmaceutical, Amneal Pharmaceuticals LLC, Trevena, Inc., Lupin, and Endo Pharmaceuticals, Inc.. These companies are focused on new product approvals and launches.

For more insights, read- https://www.newsstatix.com/oral-thin-films-market-trends-size-and-share-analysis/

For more details on the report, Read- https://cmiinfopiece.blogspot.com/2024/01/plant-based-meat-market-growth.html